HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 05-29-2019, 06:51 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Thumbs up subcutaneouss herceptin just as effective, safe as IV herceptin

JAMAOncology | BriefReport
Subcutaneous vs Intravenous Trastuzumab for Patients
With ERBB2-Positive Early Breast Cancer
Final Analysis of the HannaH Phase 3 Randomized Clinical Trial
Christian Jackisch, MD, PhD; Daniil Stroyakovskiy, MD; Xavier Pivot, MD; Jin Seok Ahn, MD; Bohuslav Melichar, MD, PhD; Shin-Cheh Chen, MD; Christoph Meyenberg, MSc; Nedal Al-Sakaff, PhD; Dominik Heinzmann, PhD; Roberto Hegg, MD, PhD


Author Affiliations: Author affiliations are listed at the end of this article.
Corresponding Author: Christian Jackisch, MD, PhD, Department of Obstetrics and Gynecology, Sana Klinikum Offenbach GmbH, Starkenburgring 66, D-63069 Offenbach, Germany (christian. jackisch@sana.de).
(Reprinted) 1/5

IMPORTANCE Confirmation of long-term comparability between subcutaneous and intravenous trastuzumab is essential.
OBJECTIVE Toevaluateefficacyandsafetyofsubcutaneoustrastuzum abcomparedwiththat of intravenous trastuzumab for patients with ERBB2 (HER2)–positive early breast cancer after 6 years’ follow-up in the HannaH (Enhanced Treatment With Neoadjuvant Herceptin) trial.
DESIGN,SETTING,ANDPARTICIPANTS Open-label,prospective,multicenter,international, neoadjuvant-adjuvant, randomized, phase 3 noninferiority clinical trial (primary end points: pathologic complete response and serum trough concentration predose cycle 8) conducted for 596 patients with ERBB2-positive early breast cancer enrolled from October 19, 2009, to December 1, 2010.
INTERVENTIONS Eligiblepatientsreceived8cyclesofchemotherapy(4cyc lesofdocetaxel, 75 mg/m2, followed by 4 cycles of fluorouracil, 500 mg/m2, epirubicin, 75 mg/m2, and cyclophosphamide, 500 mg/m2) with either fixed-dose subcutaneous trastuzumab, 600 mg, or intravenous trastuzumab (loading dose, 8 mg/kg; maintenance dose, 6 mg/kg) every 3 weeks in the neoadjuvant setting. Patients received an additional 10 cycles of subcutaneous trastuzumab or intravenous trastuzumab (according to their initial randomization) after surgery in the adjuvant setting to complete 1 year of anti-ERBB2 therapy.
MAINOUTCOMESANDMEASURES Event-freeandoverallsurvivalrateswerecalculatedusing the Kaplan-Meier method. Hazard ratios were estimated by Cox proportional hazards regression. Adverse events and serious adverse events were graded per standard criteria.
RESULTS Intotal,294women(mean[SD]age,50.3[11.1]years)treatedwithsubcutaneous trastuzumab and 297 women (mean [SD] age, 49.5 [10.8] years) treated with intravenous trastuzumab were included in respective intention-to-treat populations. Six-year event-free survival rates (65% in both study groups; hazard ratio, 0.98; 95% CI, 0.74-1.29) and overall survival rates (84% in both study groups; hazard ratio, 0.94; 95% CI, 0.61-1.45) were similar between the subcutaneous and intravenous trastuzumab groups. Patients achieving a total pathologic complete response had longer event-free survival and higher 6-year overall survival rates than those with residual disease. Incidence of adverse events (290 of 297 [97.6%] vs 282 of 298 [94.6%]), grade 3 or higher adverse events (158 of 297 [53.2%] vs 160 of 298 [53.7%]), cardiac events (44 of 297 [14.8%] vs 42 of 298 [14.1%]), and serious adverse events (65 of 297 [21.9%] vs 45 of 298 [15.1%]) was comparable between the subcutaneous and intravenous trastuzumab treatment groups.
CONCLUSIONSANDRELEVANCE ThisfinalanalysisoftheHannaHtrialfurtherconfirmsth e comparable efficacy and safety of subcutaneous and intravenous trastuzumab and highlights the suitability of subcutaneous trastuzumab as an alternative route of administration for
patients with ERBB2-positive early breast cancer. TRIALREGISTRATION ClinicalTrials.govidentifier:NCT00950300
JAMA Oncol. 2019;5(5):e190339. doi:10.1001/jamaoncol.2019.0339 Published online April 18, 2019.
Lani is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 12:29 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter